Literature DB >> 18472160

Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients.

Barbara Zdzisińska1, Adam Walter-Croneck, Martyna Kandefer-Szerszeń.   

Abstract

We have investigated the production of metalloproteinases (MMP-1, MMP-2, MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in bone marrow stromal cells (BMSCs) of patients with multiple myeloma (MM) and a healthy control. The new findings of this paper is that BMSCs of the MM patients exhibited intrinsic MMP-1, MMP-2 and TIMP-2 overproduction. Production of MMP-1, TIMP-2 and activation of MMP-2 was additionally enhanced in co-cultures of BMSCs with RPMI8226 cells. The ratio between MMP-2 and TIMP-2 was significantly higher in BMSCs of the MM patients than in control. BMSCs of both the control and the MM patients exhibited the presence of MMP-9 latent form, but in co-cultures RPMI8226 cells were the main producers of this metalloproteinase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472160     DOI: 10.1016/j.leukres.2008.04.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

Review 2.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962

Review 3.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

4.  Cell Trafficking in Multiple Myeloma.

Authors:  Giada Bianchi; Shaji Kumar; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2012-02-21

5.  Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.

Authors:  Marina Ferrarini; Nathalie Steimberg; Maurilio Ponzoni; Daniela Belloni; Angiola Berenzi; Stefania Girlanda; Federico Caligaris-Cappio; Giovanna Mazzoleni; Elisabetta Ferrero
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

6.  Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Authors:  Antonio Garcia-Gomez; Javier De Las Rivas; Enrique M Ocio; Elena Díaz-Rodríguez; Juan C Montero; Montserrat Martín; Juan F Blanco; Fermín M Sanchez-Guijo; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Oncotarget       Date:  2014-09-30

7.  Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.

Authors:  Gemma Shay; Marilena Tauro; Fulvio Loiodice; Paolo Tortorella; Daniel M Sullivan; Lori A Hazlehurst; Conor C Lynch
Journal:  Oncotarget       Date:  2017-06-27

8.  A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.

Authors:  S T Lwin; J A Fowler; M T Drake; J R Edwards; C C Lynch; C M Edwards
Journal:  Mol Cancer       Date:  2017-02-28       Impact factor: 27.401

9.  Renal Impairment Detectors: IGFBP-7 and NGAL as Tubular Injury Markers in Multiple Myeloma Patients.

Authors:  Karolina Woziwodzka; Jolanta Małyszko; Ewa Koc-Żórawska; Marcin Żórawski; Paulina Dumnicka; Artur Jurczyszyn; Krzysztof Batko; Paulina Mazur; Małgorzata Banaszkiewicz; Marcin Krzanowski; Paulina Gołasa; Jacek A Małyszko; Ryszard Drożdż; Katarzyna Krzanowska
Journal:  Medicina (Kaunas)       Date:  2021-12-10       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.